Fluidigm Announces Co-Marketing Agreement with Visiopharm to Expand and Simplify Imaging Mass Cytometry Data Analysis

September 10th, 2018

Visiopharm Phenomap software presented at the Fluidigm Imaging Mass Cytometry User Group Meeting, expanding the suite of Hyperion Imaging System data analysis tools for translational and clinical research 

Fluidigm Corporation (NASDAQ:FLDM) and Visiopharm A/S today announced a co-marketing relationship to automate image analysis for Imaging Mass Cytometry™ (IMC™). Under the terms of this agreement, Fluidigm and Visiopharm will cooperatively promote Visiopharm® image analysis software in conjunction with the Fluidigm® Hyperion™ Imaging System, MCD™ Viewer software and related Maxpar® antibodies and kits.

Read more

LAUNCHING Phenomap™ - New Automated Phenotyping Software Tool Streamlined Analysis Workflow of High Dimensional Images

September 7th, 2018

Introducing Visiopharm Phenomap™ Multiplexing a novel software tool to help you streamline and automate the analysis workflow of high dimensional multiplex datasets, for deeper understanding of potential relationships in the tumor microenvironment (TME).

Phenomap™ offers a streamlined and intuitive workflow for simultaneous analysis of up to 255 channels by automatically identifying individual cells and performing cell-based phenotyping in high dimensional multiplex images.

Researchers and scientists have a growing necessity for simultaneous analysis of multiple biomarkers to identify immune cells within the tumor microenvironment (TME). Imaging the tumor microenvironment has inherent problems as there are many different types of immune cells to identify.

Read more

Strong consortium invests nearly DKK 100 million (€ 13.3 million) into Danish image analysis leader, Visiopharm A/S

August 24th, 2018

ATP, the Danish Growth Fund and the C. L. David Foundation and Collection are among the new investors. The increased capital commitment is an essential part of the company’s growth strategy within the field of tissue diagnostics- and research software for cancer.

Visiopharm A/S, is developing software for tissue based cancer diagnostics, based on image analysis that integrates precision- and high-throughput pathology in diagnostic workflows. ATP is investing DKK 45 million, the Danish Growth Fund is putting in DKK 20 million and the C. L. David Foundation is financing with DKK 15 million. In addition, the existing investor Northcap Venture Partners has invested a further DKK 15 million. The remaining investment is supplied by smaller shareholders/owners. In addition to the investors, the owners moving forward will thus be comprised of the founders, Michael Grunkin and Johan Doré Hansen, as well as a number of smaller shareholders. The investment is the basis for further international growth.

Read more

Investorer skyder knap 100 mio. kr. i danske Visiopharm

22. august, 2018

ATP, Vækstfonden og C. L. Davids Fond og Samling er blandt de nye investorer, der skal sikre den fortsatte udvikling af Visiopharms software til brug for kræftdiagnostik. Det øgede kapitaltilsagn er et afgørende led i virksomhedens plan om en senere børsnotering i Danmark.

Visiopharm A/S, som udvikler software til billedanalyse af celler til brug i kræftdiagnostik, har sikret sig en større kapitalindsprøjtning til den videre vækst. ATP investerer således 45 mio. kr., Vækstfonden 20 mio. kr. og C. L. Davids Fond 15 mio. kr. Herudover har den eksisterende investor, Northcap Venture Partners, investeret yderligere 15 mio. kr., hvor det resterende beløb indskydes af mindre aktionærer. Foruden de nævnte investorer vil ejerkredsen således fremover bestå af stifterne Michael Grunkin og Johan Doré Hansen samt en række mindre aktionærer.

Read more